Quick Summary
Researchers searched for studies testing medications for ME/CFS and found 26 high-quality trials. While 10 medications showed some benefit in their respective studies, no single medication worked well for everyone with ME/CFS. This suggests that different patients may need different treatments, and more research is needed to find which medications help which patients.
Why It Matters
This review is crucial because ME/CFS patients often use multiple medications without clear evidence of benefit, creating unnecessary medication burden and potential side effects. By demonstrating that no single drug works universally and recommending future trials use consistent diagnostic criteria, it directs research toward identifying medication subgroups—meaning certain drugs might help certain patients rather than all patients.
Observed Findings
What the study reports it measured.
- 26 randomized controlled trials met inclusion criteria for systematic review.
- Ten medications showed statistically significant efficacy in their respective study groups (P < 0.05).
- Twenty different pharmaceutical classes were tested across the reviewed studies.
- Three different diagnostic criteria were identified among the included trials: Holmes criteria, International Consensus Criteria, and Fukuda criteria.
- Primary outcome measures varied, including fatigue, pain, mood, neurocognitive dysfunction, sleep quality, symptom severity, functional status, and well-being.
Inferred Conclusions
What the authors interpret from those results.
- No universal pharmaceutical treatment can be recommended for ME/CFS based on current evidence.
- The heterogeneous nature of ME/CFS and lack of consistent diagnostic criteria in trials complicate identification of effective treatments and patient subgroups.
- Future trials using more specific diagnostic criteria (particularly International Consensus Criteria) are needed to identify which patients may benefit from specific medications.
- The discrepancy between medication use in clinical practice and evidence-based recommendations highlights gaps in research and suggests patients require better guidance on treatment options.
Remaining Questions
- Which patient subgroups, defined by specific biological or clinical characteristics, would benefit from which pharmaceutical interventions?
- How do the three diagnostic criteria identify different patient populations, and do treatment responses differ systematically across these groups?
- What is the optimal study design and outcome measurement approach to detect pharmaceutical efficacy in ME/CFS populations?
- Why do patients use medications without clear evidence of benefit, and what information would better support shared decision-making in clinical practice?
What This Study Does Not Prove
This review does not prove that medications are ineffective for ME/CFS—only that current evidence is insufficient and contradictory. It does not establish which biological mechanisms (if any) medications successfully target, nor does it identify which patient subgroups might benefit from specific treatments. The exclusion of combined pharmacological and behavioral interventions means this review does not address how drugs might work alongside other approaches.
Explore further
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Cite this study
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Collatz, Ansel, Johnston, Samantha C, Staines, Donald R, & Marshall-Gradisnik, Sonya M (2016). A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.. Clinical therapeutics. https://doi.org/10.1016/j.clinthera.2016.04.038
BibTeX
@article{mecfsatlas-collatz-2016-systematic-review,
author = {Collatz, Ansel and Johnston, Samantha C and Staines, Donald R and Marshall-Gradisnik, Sonya M},
title = {A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.},
journal = {Clinical therapeutics},
year = {2016},
doi = {10.1016/j.clinthera.2016.04.038},
note = {PubMed: 27229907},
url = {https://www.mecfsatlas.com/evidence/collatz-2016-systematic-review},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/collatz-2016-systematic-review
Contribute
Private, reviewed by a human. Not a public comment thread.